163 related articles for article (PubMed ID: 33567829)
1. Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin.
Khoza-Shangase K; Prodromos M
S Afr J Commun Disord; 2021 Jan; 68(1):e1-e8. PubMed ID: 33567829
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
[TBL] [Abstract][Full Text] [Related]
3. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
5. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
7. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
8. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.
Ghafari N; Court R; Chirehwa MT; Wiesner L; Petersen L; Maartens G; Gumbo T; McIlleron H; Ramma L
Int J Audiol; 2020 Mar; 59(3):219-223. PubMed ID: 31739701
[No Abstract] [Full Text] [Related]
10. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.
Appana D; Joseph L; Paken J
S Afr J Commun Disord; 2016 Nov; 63(1):e1-e12. PubMed ID: 28155306
[TBL] [Abstract][Full Text] [Related]
11. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
[TBL] [Abstract][Full Text] [Related]
12. An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series.
Hollander C; Joubert K; Schellack N
JMIR Mhealth Uhealth; 2020 Jan; 8(1):e14036. PubMed ID: 31934875
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review.
Singh L; Mathibe LJ; Bangalee V
Health SA; 2021; 26():1708. PubMed ID: 34917407
[TBL] [Abstract][Full Text] [Related]
14. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.
Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
S Afr J Commun Disord; 2022 Mar; 69(1):e1-e13. PubMed ID: 35384675
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
[TBL] [Abstract][Full Text] [Related]
18. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Womens Health; 2021 Apr; 21(1):164. PubMed ID: 33879158
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
20. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
Olayanju O; Limberis J; Esmail A; Oelofse S; Gina P; Pietersen E; Fadul M; Warren R; Dheda K
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29700106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
